Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.26 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: tarenflurbil, rg-4733, begacestat +4 | 0.90 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 4 Parkinson's papers of 78 | 0.79 |
| pathways Reactome | 13 pathways; mostly growth signalling | 0.60 |
No case: the score is under the bar. Receipt 1566
Sealed predictions
- APH1B in dopamine neurons, braak-0.18 (p 0.648) → +0.18 (p 0.638)receipt 1572
Swarm cases
receipt 1572: APH1B in dopamine neurons, braak
- power
- full sample -0.02 (p 0.949, n 18), 95% CI -0.48 to +0.45. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.01 (p 0.969, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.01 (p 0.969, n 18). could be the mix.
- skeptic
- leave-one-out range -0.13 to +0.09, sign flips 7; without severely affected donors -0.02 (p 0.949, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for APH1B in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts